Physician profile
Alan Plauka
NPI 1316954589
$3,612.41
in general payments reported to CMS, 2019-2025
28 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $305 · 2021: $238 · 2022: $520 · 2023: $597 · 2024: $836 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.99 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,018.37 | 2022-2025 | |
| Novo Nordisk INC | $518.17 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $300.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $292.25 | 2019-2025 | Verquvo, Belsomra |
| Glaxosmithkline, LLC. | $202.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $194.09 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Exact Sciences Corporation | $167.71 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $132.54 | 2020-2024 | |
| Medtronic, INC. | $73.72 | 2025 | Minimed 780g |
| Irhythm Technologies, INC. | $71.09 | 2022-2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $68.67 | 2019-2025 | Farxiga |
| Ardelyx, INC. | $63.15 | 2024 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $56.72 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.48 | 2019-2023 | Jardiance |
| Dexcom, INC. | $56.35 | 2021-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $55.89 | 2019-2023 | Xarelto |
| Abbvie INC. | $40.87 | 2021 | |
| Pfizer INC. | $34.72 | 2024 | |
| Allergan, INC. | $34.08 | 2019-2020 | |
| Amgen INC. | $30.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $28.64 | 2024-2025 | Zoryve |
| Horizon Therapeutics Plc | $25.21 | 2022 | |
| Corcept Therapeutics | $18.43 | 2025 | Korlym |
| Cleerly, INC. | $16.70 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Boston Scientific Corporation | $16.03 | 2022 | |
| Mannkind Corporation | $14.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.22 | 2019 | |
| Amarin Pharma, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Plauka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.